Research & Development
Blood-based MDx test developer DiamiR to present poster on trial findings at CTAD
The poster will be presented during the session “Clinical trials: Biomarkers including plasma” during the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco from November 29 to December 2.
November 28, 2022
Alzheimer’s test developer Diadem joins DPUK
Diadem's AlzoSure Predict blood test identifies signs of cognitive impairment that will or will not progress to Alzheimer's dementia up to six years before diagnosis.
June 12, 2022
Sysmex, Eisai tout Alzheimer's research at AD/PD 2022
As part of a nonexclusive agreement to create diagnostic agents for dementia, researchers from the companies compared the performance of the plasma beta-amyloid ratio measured using the Sysmex HISCL automated immunoassay system with that of amyloid status on positron emission tomography (PET) imaging as determined by the Centiloid method. Their technique was assessed in a discovery study in 180 patients and in a validation study involving 191 patients who were clinically diagnosed with mild Alzheimer's disease or mild cognitive impairment.
March 22, 2022
Spinal fluid tests may aid PET scans of Alzheimer's disease
A Swiss group led by senior author Michael Schöll, PhD, of the University Gothenburg investigated whether fluid and blood biomarkers that indicate Alzheimer's disease could predict the accumulation of neurofibrillary tau tangles seen on PET scans in patients diagnosed with the disease. They found the lab tests performed well enough to help select patients for PET imaging studies evaluating new treatments.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Brain surface renderings depict Pearson correlation coefficients adjusted for age and sex (r) representing the strength of the association between the different biomarkers and F-18 flortaucipir SUVR change in each brain region. The right upper panel represents age- and sex-adjusted Pearson correlation coefficients (r), along with p-values, for the association between the biomarkers and F-18 flortaucipir SUVR change in the Alzheimer's disease meta-region of interest (ROI). The root mean squared error (RMSE) for the prediction of F-18 flortaucipir SUVR change by a linear model with the biomarker as predictor and age and sex as covariates. RMSE was estimated using leave-one-out cross-validation. Voxel-wise statistical maps were thresholded using more lenient cluster-forming thresholds of p < 0.05 (uncorrected) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
March 3, 2022
SDx partners with I-Ally on Alzheimer's test
The partnership's goal is to help caregivers get a diagnosis quickly for Alzheimer's disease in patients, as well as raising Alzheimer's awareness early in patients diagnosed with dementia.
February 24, 2022
Neurodegenerative markers found in COVID-19 patients
Researchers at New York University (NYU) analyzed the serum of 251 hospitalized COVID-19 patients without a history of dementia, in particular looking for neurodegenerative markers. These included total tau (t-tau), phosphorylated tau-181 (p-tau181), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and beta-amyloid (Aβ40,42).
January 12, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Patients prefer immediate test results, even when the news is bad
Quest Diagnostics offers suite of services for transplant patients and living donors
Synaps Dx's Alzheimer's disease test gets payment code
The Discern test is the first autopsy-validated, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's disease dementias to earn PLA codes 206U and 207U, Synaps Dx said.
November 8, 2021
NeuroVision receives funding to develop dementia blood test
The Sacramento, CA-based company will develop an "ultramultiplex assay" to measure multiple blood biomarkers that are associated with the development of dementia, it said. Additionally, the project will further NeuroVision's work on a proprietary blood assay that appears to mirror beta-amyloid protein load in the brain, the company noted.
August 23, 2021
Inflammatory marker sCD14 lurks in dementia
Earlier detection of dementia using convenient blood tests is an important goal for Alzheimer's disease and other dementia disorders so that patients can be identified in time to be included in clinical trials and hopefully treated successfully. Inflammation and infection have become intriguing areas of research in Alzheimer's disease.
December 10, 2019
Researchers to study media coverage of 'overdiagnosis' tests
Dr. Mary O'Keeffe from the University of Sydney and colleagues will investigate media coverage of the following five tests:
August 26, 2019
AAIC update: Where blood-based dementia tests stand in 2019
Among three studies of blood tests flagged by meeting organizers was a report from Dr. Akinori Nakamura, PhD, of the National Center for Geriatrics and Gerontology in Obu, Japan, and colleagues that biomarker composite derived from ratios of plasma levels of amyloid-related peptides -- amyloid-β precursor protein (APP)669-711/amyloid-β (Aβ)1-42 and Aβ1-40/Aβ1-42 -- and tested with mass spectrometry were significantly correlated with results for beta amyloid as measured with PET scans. The study included 201 samples from patients seen in three Japanese centers, including patients with Alzheimer's disease, mild cognitive impairment, and non-Alzheimer's dementia.
July 15, 2019
Cerebrospinal fluid test helps pinpoint dementia disorders
The meta-analysis of studies involving about 10,000 people with neurological disorders showed that neurofilament light protein as measured with a commercially available immunoassay was elevated for people with neurological and psychiatric conditions. Results were broadly similar; however, frontotemporal dementia and HIV-related cognitive decline were differentiated from other dementias, and Parkinson's disease was differentiated from atypical parkinsonian conditions.
June 17, 2019
Page 1 of 2